表紙
市場調查報告書
商品編碼
236772

醫藥品受託製造的全球市場

Pharmaceutical Contract Manufacturing

出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 528 Pages | 商品交期: 最快1-2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供全球醫藥品受託製造市場相關調查,市場概要及預測,各地區趨勢,及打入市場的主要企業簡介等彙整資料。

第1章 簡介,調查方法,產品定義

第2章 摘要整理

  • 產業概要
    • 醫藥品受託製造:概要
    • 現在及未來分析
    • 市場規模
    • 醫藥品受託製造服務由歐美領先
    • 固定用量在CMO內現在仍受歡迎
    • 注射型製劑牽引PCM市場成長
    • PMC市場機會
    • 推動市場的要素
    • 為了實現明亮的未來需要大變革
  • 市場趨勢和促進因素
  • 競爭環境
  • 服務概要
    • 簡介
    • 注射型藥物
    • 固定用量製劑
    • 液狀製劑
    • 醫藥品受託製造的增加
    • 投資風險
    • 品質保證風險
    • 藥物開發風險
    • 收購風險
    • 客戶依存風險
  • 近幾年的產業活動
  • 主要加入企業
    • Aenova Group
    • Ajinomoto Althea, Inc.
    • Albany Molecular Research Inc.
    • Alcami Corporation
    • Baxter International, Inc.
    • Boehringer Ingelheim GmbH
    • Catalent Pharma Solutions, Inc.
    • Cobra Biologics Holding AB
    • CordenPharma International
    • Dishman Group
    • DPx Holdings B.V.
    • Fareva Group
    • Famar Health Care Services
    • Hospira, Inc.
    • Jubilant Life Sciences Limited
    • Kemwell Biopharma Pvt. Ltd.
    • Lonza Group Ltd.
    • LTS Lohmann Therapie-Systeme AG
    • NextPharma Technologies Holding Ltd.
    • Nipro Pharma株式會社
    • Recipharm AB
  • 全球市場預測

第3章 市場

  • 美國
  • 日本
  • 歐洲
  • 亞太地區
  • 其他
目錄
Product Code: MCP-1535

Abstract:

Global Pharmaceutical Contract Manufacturing Market to Reach $130.2 Billion by 2026

Pharmaceutical contract manufacturing refers to outsourcing of the manufacturing function of pharmaceutical products. Outsourcing manufacturing processes allows hiring pharmaceutical companies to allocate its precious resources on core competencies - drug research and product commercialization. Growth in the global market is set to be driven by positive trends in the broader pharmaceuticals market which is in turn driven by growth in the emerging markets. The robust demand for medication and therapeutics in the emerging economies, coupled with the increasing commercialization of generics and emerging technologies are anticipated to spur growth in the market. With the market gradually inching towards biopharmaceuticals, with several of such drugs being developed by start-up or smaller biotech companies who either have no or limited production capabilities is also fueling growth in pharmaceutical contract services. Increasing geriatric patient population, growing consumption of medicines, rising healthcare expenditure, improvising healthcare infrastructure in emerging markets and mounting pressure to reduce healthcare costs are other factors driving market growth.

Amid the COVID-19 crisis, the global market for Pharmaceutical Contract Manufacturing estimated at US$100 Billion in the year 2020, is projected to reach a revised size of US$130.2 Billion by 2026, growing at a CAGR of 4.6% over the analysis period. API/Bulk Drugs, one of the segments analyzed in the report, is projected to record a 4.4% CAGR and reach US$81.5 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Advanced Drug Delivery Formulations segment is readjusted to a revised 3.8% CAGR for the next 7-year period.

The U.S. Market is Estimated at $31.6 Billion in 2021, While China is Forecast to Reach $21.1 Billion by 2026

The Pharmaceutical Contract Manufacturing market in the U.S. is estimated at US$31.6 Billion in the year 2021. China, the world`s second largest economy, is forecast to reach a projected market size of US$21.1 Billion by the year 2026 trailing a CAGR of 5.6% over the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.6% and 4.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR. The presence of a significant number of pharmaceutical and biopharmaceutical companies, and several of the leading firms worldwide, together sizable number of contract manufacturers puts the US and Europe ahead in the global market. The US represents the largest market, driven by healthcare reforms and the replacement of branded drugs with generics following patent expiries of these drugs. Lower labor costs, presence of significant talent pool and growing domestic markets are some of the factors driving growth in the Asia-Pacific region.

Packaging Segment to Reach $15.6 Billion by 2026

Contract manufacturing organizations are increasingly adopting newer and efficient ways to packaging, thereby increasing demand for new machinery. Efforts are underway to automate packaging of personalized cell and gene therapies. In the global Packaging segment, USA, Canada, Japan, China and Europe will drive the 4.8% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$8 Billion in the year 2020 will reach a projected size of US$11.3 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$3.4 Billion by the year 2026.

Select Competitors (Total 192 Featured) -

  • Abbvie Inc
  • Aenova Group
  • Ajinomoto Althea, Inc.
  • Alcami Corporation
  • Almac Group
  • Baxter International, Inc.
  • Boehringer Ingelheim GmbH
  • Catalent Pharma Solutions, Inc.
  • Cobra Biologics Holding AB
  • CordenPharma International
  • Dishman Group
  • Evonik Industries AG
  • Famar Health Care Services
  • Fareva Group
  • Jubilant Life Sciences Limited
  • Kemwell Biopharma Pvt. Ltd.
  • Lonza Group Ltd.
  • LTS Lohmann Therapie-Systeme AG
  • NextPharma Technologies Holding Ltd.
  • Nipro Pharma Corporation
  • Recipharm AB
  • Siegfried AG
  • Thermo Fisher Scientific Inc
  • Vetter Pharma International GmbH

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Pharmaceutical Contract Manufacturing - A Prelude
    • COVID-19 Breaks All Things Normal, Pushes Pharmaceutical Industry Into an Era of Change
    • COVID-19 Exposes US Pharmaceutical Makers to Risk of Supply Shortages
    • US Federal Government & FDA Take Unprecedented, Bold Steps to Deal with Shortage of Pharmaceuticals
    • What Does this Spell for Pharmaceutical Outsourcing & Contract Manufacturing?
    • Market Outlook
    • The US and Europe Constitute the Largest Markets for PCM
    • Asia-Pacific to Drive the PCM Market Growth
    • Competition
    • M&A Activity High in the Contract Manufacturing Space
  • 2. FOCUS ON SELECT PLAYERS
    • Recent Market Activity
  • 3. MARKET TRENDS & DRIVERS
    • Strong Rise in Pharmaceutical Sales to Drive Demand for Pharmaceutical Contract Manufacturing
    • EXHIBIT 1: Global Prescription Drug Sales (In US$ Billion) for the Years 2017, 2019, 2021, 2023 & 2025
    • Emergence of Outsourcing Trend Bodes Well for CDMOs
    • Pharmaceutical Contract Manufacturers Adopt Advanced Manufacturing Technologies
    • Embracing Emerging Technologies
    • Exploring & Exploiting New Technologies for Rich Dividends
    • Rapid Growth of Generic Drugs Drives Demand for Pharma Contract Manufacturing
    • EXHIBIT 2: Leading Drugs Facing Patent Expiry in the US in 2020
    • EXHIBIT 3: Global Generic Drugs Market Size (in $ Billion) for the Years 2016, 2019, 2020 & 2025
    • Increasing Significance of Biologic Drugs Fuels Innovations Supports Demand for Pharmaceutical Contract Manufacturing Market
    • EXHIBIT 4: Global Biologic Drugs Market Size (in US$ Billion) for the Years 2019, 2022 & 2025
    • Aging Population & Increasing Burden of Chronic Diseases Spurs Pharma Product Sales, Driving Market Growth
    • EXHIBIT 5: Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
    • EXHIBIT 6: Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
    • EXHIBIT 7: World Diabetes and Population Statistics (2019, 2030 & 2045)
    • Persistent Increase in Pharmaceutical R&D Bodes Well for PCM
    • Pharmaceutical R&D Spending Worldwide (USD Billion): 2015-2025
    • Increasing Sales of OTC Drugs Presents an Opportunity for Pharma Contract Manufacturing Market
    • EXHIBIT 8: Global OTC Drugs Market Breakdown by Product (in %): 2020E
    • Increasing Outsourcing of Clinical Trials to Emerging Markets
    • New Technology Promises to Improve Sterile Manufacturing Process
    • Serialization Drives New Design Developments in Pharma Sector
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Pharmaceutical Contract Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Pharmaceutical Contract Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Pharmaceutical Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for API/Bulk Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for API/Bulk Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for API/Bulk Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Advanced Drug Delivery Formulations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Advanced Drug Delivery Formulations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Advanced Drug Delivery Formulations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Packaging by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Packaging by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Packaging by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for Finished Dose Formulations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for Finished Dose Formulations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for Finished Dose Formulations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 16: World Current & Future Analysis for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 17: World Historic Review for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 18: World 15-Year Perspective for Other Product Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 19: World Current & Future Analysis for Pharmaceutical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 20: World Historic Review for Pharmaceutical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 21: World 15-Year Perspective for Pharmaceutical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 22: World Current & Future Analysis for Biopharmaceutical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 23: World Historic Review for Biopharmaceutical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 24: World 15-Year Perspective for Biopharmaceutical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 25: World Current & Future Analysis for Sterile by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 26: World Historic Review for Sterile by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 27: World 15-Year Perspective for Sterile by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 28: World Current & Future Analysis for Non-Sterile by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 29: World Historic Review for Non-Sterile by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 30: World 15-Year Perspective for Non-Sterile by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 31: USA Current & Future Analysis for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 32: USA Historic Review for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 33: USA 15-Year Perspective for Pharmaceutical Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types for the Years 2012, 2020 & 2027
    • TABLE 34: USA Current & Future Analysis for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 35: USA Historic Review for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 36: USA 15-Year Perspective for Pharmaceutical Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Pharmaceutical and Biopharmaceutical for the Years 2012, 2020 & 2027
    • TABLE 37: USA Current & Future Analysis for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 38: USA Historic Review for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 39: USA 15-Year Perspective for Pharmaceutical Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Sterile and Non-Sterile for the Years 2012, 2020 & 2027
  • CANADA
    • TABLE 40: Canada Current & Future Analysis for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 41: Canada Historic Review for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 42: Canada 15-Year Perspective for Pharmaceutical Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types for the Years 2012, 2020 & 2027
    • TABLE 43: Canada Current & Future Analysis for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 44: Canada Historic Review for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 45: Canada 15-Year Perspective for Pharmaceutical Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Pharmaceutical and Biopharmaceutical for the Years 2012, 2020 & 2027
    • TABLE 46: Canada Current & Future Analysis for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 47: Canada Historic Review for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 48: Canada 15-Year Perspective for Pharmaceutical Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Sterile and Non-Sterile for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 49: Japan Current & Future Analysis for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 50: Japan Historic Review for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 51: Japan 15-Year Perspective for Pharmaceutical Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types for the Years 2012, 2020 & 2027
    • TABLE 52: Japan Current & Future Analysis for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 53: Japan Historic Review for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 54: Japan 15-Year Perspective for Pharmaceutical Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Pharmaceutical and Biopharmaceutical for the Years 2012, 2020 & 2027
    • TABLE 55: Japan Current & Future Analysis for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 56: Japan Historic Review for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 57: Japan 15-Year Perspective for Pharmaceutical Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Sterile and Non-Sterile for the Years 2012, 2020 & 2027
  • CHINA
    • TABLE 58: China Current & Future Analysis for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 59: China Historic Review for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 60: China 15-Year Perspective for Pharmaceutical Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types for the Years 2012, 2020 & 2027
    • TABLE 61: China Current & Future Analysis for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 62: China Historic Review for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 63: China 15-Year Perspective for Pharmaceutical Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Pharmaceutical and Biopharmaceutical for the Years 2012, 2020 & 2027
    • TABLE 64: China Current & Future Analysis for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 65: China Historic Review for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 66: China 15-Year Perspective for Pharmaceutical Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Sterile and Non-Sterile for the Years 2012, 2020 & 2027
  • EUROPE
    • TABLE 67: Europe Current & Future Analysis for Pharmaceutical Contract Manufacturing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 68: Europe Historic Review for Pharmaceutical Contract Manufacturing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 69: Europe 15-Year Perspective for Pharmaceutical Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 70: Europe Current & Future Analysis for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 71: Europe Historic Review for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 72: Europe 15-Year Perspective for Pharmaceutical Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types for the Years 2012, 2020 & 2027
    • TABLE 73: Europe Current & Future Analysis for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 74: Europe Historic Review for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 75: Europe 15-Year Perspective for Pharmaceutical Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Pharmaceutical and Biopharmaceutical for the Years 2012, 2020 & 2027
    • TABLE 76: Europe Current & Future Analysis for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 77: Europe Historic Review for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 78: Europe 15-Year Perspective for Pharmaceutical Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Sterile and Non-Sterile for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 79: France Current & Future Analysis for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 80: France Historic Review for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 81: France 15-Year Perspective for Pharmaceutical Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types for the Years 2012, 2020 & 2027
    • TABLE 82: France Current & Future Analysis for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 83: France Historic Review for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 84: France 15-Year Perspective for Pharmaceutical Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Pharmaceutical and Biopharmaceutical for the Years 2012, 2020 & 2027
    • TABLE 85: France Current & Future Analysis for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 86: France Historic Review for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 87: France 15-Year Perspective for Pharmaceutical Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Sterile and Non-Sterile for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 88: Germany Current & Future Analysis for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 89: Germany Historic Review for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 90: Germany 15-Year Perspective for Pharmaceutical Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types for the Years 2012, 2020 & 2027
    • TABLE 91: Germany Current & Future Analysis for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 92: Germany Historic Review for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 93: Germany 15-Year Perspective for Pharmaceutical Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Pharmaceutical and Biopharmaceutical for the Years 2012, 2020 & 2027
    • TABLE 94: Germany Current & Future Analysis for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 95: Germany Historic Review for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 96: Germany 15-Year Perspective for Pharmaceutical Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Sterile and Non-Sterile for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 97: Italy Current & Future Analysis for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 98: Italy Historic Review for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 99: Italy 15-Year Perspective for Pharmaceutical Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types for the Years 2012, 2020 & 2027
    • TABLE 100: Italy Current & Future Analysis for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 101: Italy Historic Review for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 102: Italy 15-Year Perspective for Pharmaceutical Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Pharmaceutical and Biopharmaceutical for the Years 2012, 2020 & 2027
    • TABLE 103: Italy Current & Future Analysis for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 104: Italy Historic Review for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 105: Italy 15-Year Perspective for Pharmaceutical Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Sterile and Non-Sterile for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 106: UK Current & Future Analysis for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 107: UK Historic Review for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 108: UK 15-Year Perspective for Pharmaceutical Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types for the Years 2012, 2020 & 2027
    • TABLE 109: UK Current & Future Analysis for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 110: UK Historic Review for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 111: UK 15-Year Perspective for Pharmaceutical Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Pharmaceutical and Biopharmaceutical for the Years 2012, 2020 & 2027
    • TABLE 112: UK Current & Future Analysis for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 113: UK Historic Review for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 114: UK 15-Year Perspective for Pharmaceutical Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Sterile and Non-Sterile for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 115: Rest of Europe Current & Future Analysis for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 116: Rest of Europe Historic Review for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 117: Rest of Europe 15-Year Perspective for Pharmaceutical Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types for the Years 2012, 2020 & 2027
    • TABLE 118: Rest of Europe Current & Future Analysis for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 119: Rest of Europe Historic Review for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 120: Rest of Europe 15-Year Perspective for Pharmaceutical Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Pharmaceutical and Biopharmaceutical for the Years 2012, 2020 & 2027
    • TABLE 121: Rest of Europe Current & Future Analysis for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 122: Rest of Europe Historic Review for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 123: Rest of Europe 15-Year Perspective for Pharmaceutical Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Sterile and Non-Sterile for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 124: Asia-Pacific Current & Future Analysis for Pharmaceutical Contract Manufacturing by Geographic Region - India and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 125: Asia-Pacific Historic Review for Pharmaceutical Contract Manufacturing by Geographic Region - India and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 126: Asia-Pacific 15-Year Perspective for Pharmaceutical Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for India and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027
    • TABLE 127: Asia-Pacific Current & Future Analysis for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 128: Asia-Pacific Historic Review for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 129: Asia-Pacific 15-Year Perspective for Pharmaceutical Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types for the Years 2012, 2020 & 2027
    • TABLE 130: Asia-Pacific Current & Future Analysis for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 131: Asia-Pacific Historic Review for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 132: Asia-Pacific 15-Year Perspective for Pharmaceutical Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Pharmaceutical and Biopharmaceutical for the Years 2012, 2020 & 2027
    • TABLE 133: Asia-Pacific Current & Future Analysis for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 134: Asia-Pacific Historic Review for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 135: Asia-Pacific 15-Year Perspective for Pharmaceutical Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Sterile and Non-Sterile for the Years 2012, 2020 & 2027
  • INDIA
    • TABLE 136: India Current & Future Analysis for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 137: India Historic Review for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 138: India 15-Year Perspective for Pharmaceutical Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types for the Years 2012, 2020 & 2027
    • TABLE 139: India Current & Future Analysis for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 140: India Historic Review for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 141: India 15-Year Perspective for Pharmaceutical Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Pharmaceutical and Biopharmaceutical for the Years 2012, 2020 & 2027
    • TABLE 142: India Current & Future Analysis for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 143: India Historic Review for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 144: India 15-Year Perspective for Pharmaceutical Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Sterile and Non-Sterile for the Years 2012, 2020 & 2027
  • REST OF ASIA-PACIFIC
    • TABLE 145: Rest of Asia-Pacific Current & Future Analysis for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 146: Rest of Asia-Pacific Historic Review for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 147: Rest of Asia-Pacific 15-Year Perspective for Pharmaceutical Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types for the Years 2012, 2020 & 2027
    • TABLE 148: Rest of Asia-Pacific Current & Future Analysis for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 149: Rest of Asia-Pacific Historic Review for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 150: Rest of Asia-Pacific 15-Year Perspective for Pharmaceutical Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Pharmaceutical and Biopharmaceutical for the Years 2012, 2020 & 2027
    • TABLE 151: Rest of Asia-Pacific Current & Future Analysis for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 152: Rest of Asia-Pacific Historic Review for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 153: Rest of Asia-Pacific 15-Year Perspective for Pharmaceutical Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Sterile and Non-Sterile for the Years 2012, 2020 & 2027
  • REST OF WORLD
    • TABLE 154: Rest of World Current & Future Analysis for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 155: Rest of World Historic Review for Pharmaceutical Contract Manufacturing by Product Type - API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 156: Rest of World 15-Year Perspective for Pharmaceutical Contract Manufacturing by Product Type - Percentage Breakdown of Value Sales for API/Bulk Drugs, Advanced Drug Delivery Formulations, Packaging, Finished Dose Formulations and Other Product Types for the Years 2012, 2020 & 2027
    • TABLE 157: Rest of World Current & Future Analysis for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 158: Rest of World Historic Review for Pharmaceutical Contract Manufacturing by Application - Pharmaceutical and Biopharmaceutical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 159: Rest of World 15-Year Perspective for Pharmaceutical Contract Manufacturing by Application - Percentage Breakdown of Value Sales for Pharmaceutical and Biopharmaceutical for the Years 2012, 2020 & 2027
    • TABLE 160: Rest of World Current & Future Analysis for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 161: Rest of World Historic Review for Pharmaceutical Contract Manufacturing by End-Use - Sterile and Non-Sterile Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 162: Rest of World 15-Year Perspective for Pharmaceutical Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Sterile and Non-Sterile for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 192